EGFR and cancer: Only 67% of the CSF samples were positive for genomic aberrations, 44% contained mutations in cancer driver genes, such as EGFR, ALK, MET, BRAF, ROS1, NTRK1, RET, KRAS, and ERBB2 [22], and 51% contained oncogenic mutations defined by the oncoKB database [23].